Elevance: Checking Out The Q3 Report
Elevance Health reported Q3 results, beating consensus earnings estimates. However, the beat was due to one-off items. Key focus areas include Medical Cost Ratio stabilization, 2026 premium rate re-filings, updates on Medicare segment growth, and membership trends for ELV. The benefit expense ratio continues to be elevated; the outlook for 2026 is for further deterioration in Medicaid results; however, there was no detailed data on rate re-filings.
Elevance Health Q3 Earnings Beat Estimates on Strong MA Membership
ELV beats EPS estimates by 21% in Q3 as strong Medicare Advantage membership gains and Carelon revenue growth offset Medicaid losses.
Elevance Health, Inc. (ELV) Q3 2025 Earnings Call Transcript
Elevance Health, Inc. (NYSE:ELV ) Q3 2025 Earnings Call October 21, 2025 8:30 AM EDT Company Participants Nathan Rich - Vice President of Investor Relations Gail Boudreaux - President, CEO & Director Mark Kaye - Executive VP & CFO Felicia Norwood - Executive VP & President of Government Health Benefits Peter Haytaian - Executive VP and President of Carelon & CarelonRx Conference Call Participants Albert Rice - UBS Investment Bank, Research Division Stephen Baxter - Wells Fargo Securities, LLC, Research Division Lisa Gill - JPMorgan Chase & Co, Research Division Andrew Mok - Barclays Bank PLC, Research Division Justin Lake - Wolfe Research, LLC Lance Wilkes - Sanford C. Bernstein & Co., LLC.
Is ELV's Push Beyond Insurance a Blueprint for the Healthcare Future?
Elevance Health expands beyond insurance into primary care, digital health and pharmacy services, aiming to reshape healthcare delivery.
Can Elevance Health's Value-Based Care Strategy Fuel Long-Term Growth?
ELV's focus on value-based care, Carelon integration and CareBridge acquisition drives membership and revenue growth.
Elevance Health - Piggy Bank Or Headache?
Elevance and peers face earnings pressure from rising medical costs, driven by deferred care, expensive drugs, and persistent medical inflation. The segment has re-rated, and now offers good value. Investor sentiment has returned, and capital is rotating into healthcare.
Elevance Shoots for the Stars But Lands at 3.5: $375M Bonus Gone?
Federal judge dismisses ELV's lawsuit challenging Medicare Advantage star ratings, leading to a $375M bonus loss tied to its star score.
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
ELV partners with NACHC to bring Food as Medicine into primary care, targeting nutritional insecurities and chronic disease.
When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion
ELV trims 2025 outlook as medical costs climb, but commercial growth and Carelon's momentum aim to steady performance.
When a Healthcare Giant Gets Sick: Elevance Health's 20% YTD Decline
ELV's 20% YTD slump reflects shrinking memberships, rising costs and deepening analyst pessimism despite long-term growth levers.
3 Stocks That Could Double Before 2027
These stocks have high upside potential through 2027. They're sitting at solid discounts and have good fundamentals.
Elevance Health: CEO Buys As CareBridge Drives Strong Growth
On July 18, the CEO bought $2.4MM worth, after the sell-off following the last earnings call. Carelon Services is growing fast, supported by the December acquisition of CareBridge. The aging population, the rising interest in well-being, and the potential expansion in Florida and Texas are a ray of light in the current gloomy context of the company.
